EXPLORANCE
Explorance, the leading provider of Learning Journey Analytics (LJA) solutions doubled its European client base in the past year. With the opening of new European offices, Explorance will be able to better partner with its growing European clients.
Improving the quality and relevance of teaching and learning in the European higher education market is the centre of the Bologna Process. The Yerevan Communiqué strengthened the call for better visibility of this policy area. According to the EUA Trends 2018 survey, 90% of the institutions use student feedback surveys to assess and enhance the quality of teaching. As the Bologna Process entices institutions to embrace a digitally-enabled approach, more institutions move toward the strategic use of digital tools to measure learning and teaching improvements.
“Before implementing Blue, we were using a dozen or so traditional questionnaires, combined with a few digital surveys. The wide range of individual solutions made it impossible to take full benefit of course evaluations,” says Mustapha Ali El-Ahmad, Senior Evaluation Consultant and Analyst at the Aarhus University. He adds, “Blue combines all these different questionnaires into one single solution, cleaning the data from the LMS & SIS, and automating the data analysis, while accommodating to different schools’ requirements.” Explorance’s Blue is built to support various feedback processes including course evaluations, competency development assessment, midterm reviews, applicant feedback, alumni perception analysis, student satisfaction, organisational surveys, and 360 degree reviews.
“The surge in demand for Explorance software and services in Europe indicates a growing need for proven online teaching and learning evaluation tools and increased trust in the Blue solution,” commented Ian Haugh, General Manager of the European offices. The new European office is located in Amsterdam and coordinates local activities across Europe and the UK. Local professional services are offered across Europe and customer service is provided 24/7 in multiple languages.
Blue surveys and evaluation solutions are fully localised with English, French, Spanish, German, Dutch, Swedish, Norwegian, Danish, Icelandic, Italian, Russian and Portuguese support. To support student mobility, Blue allows multiple languages to be used in one implementation at the same time. For an evaluation of your organisation’s needs, contact Explorance for a demonstration .
About Explorance
Explorance is a Learning Journey Analytics (LJA) provider that supports organisations in making the right decisions using fact-based feedback data. Through its Blue suite of products, organisations can assess needs, expectations, competencies, and monitor improvement over time.
Founded in 2003, Explorance is a privately held corporation headquartered in Montreal, Canada with business units in America, APAC, Europe, and the MENA region. As of 2014, Explorance has been ranked top employer by the Great Places to Work Institute®. Explorance's clients span a wide variety of learning organisations including academia, consulting firms, government institutions, and corporations. Learn more about Explorance .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180930005020/en/
Contact:
Gil Gruber gil@directobjective.com +1.514.238.7766
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom